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Treatment Update for Correctional HIV
providers: News from Chicago
Anne S. De Groot, M.D.*, Brown Medical School,
Editor, HEPP News

HIV experts unanimously agreed on three
aspects of HIV management during the 8th
national Conference on Retroviruses and
Opportunistic Infections (8th CROI), held in
Chicago during Feb 3-5 of this year. The three
points of agreement were: promoting voluntary
testing, improving access to care, and the
need for new approaches to eradicating latent
HIV after initiating treatment with HAART.
This article reviews presentations at the conference that were relevant to the management
of HIV in corrections, including (1) viral eradication; (2) new aspects of the HHS guidelines
for HIV management including management
of drug resistance and the application of genotyping in clinical practice, (3) new drugs in the
HIV treatment pipeline, and (4) structured
treatment interruption.

Viral Eradication: The
Elusive Holy Grail?

Bob Siliciano of Johns Hopkins University
reviewed the status of HIV eradication in the
Monday opening plenary. It is well known that
Highly Active Antiretroviral Therapy (HAART)
effectively interrupts replication of the virus in
activated T cells in the blood, reducing viral
loads but not completely eradicating the virus.
The identity of the reservoir of latent virus has
been debated. Dr. Silicano focused his talk on
the population of memory T cells that harbor
latent virus in a form that is directly integrated
into the T cell DNA. When these cells divide,
as they do at a low rate approximately every 6
months, the viral genes are transferred to
daughter T memory cells. Current antiretroviral
medications do not have any impact on the
perpetuation of this viral reservoir, due to their
action on viral proteins (not host and viral gene
replication). Thus, no amount of HAART will
ever eradicate the virus from the T memory
cell reservoir. Newer treatments that attack
integrated viral DNA are needed if viral eradication is to be achieved.
There was one bright note in this discussion:
new evidence from Dr. Silicano's laboratory
appears to confirm that effective HAART can
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reduce viral replication to zero. Patients with a
history of having been adherent to HAART
over several years continued to harbor virus
that was resistant to previously used drugs,
but no new mutations occurred. This data suggests that fully suppressive treatment of HIV
creates a viral reservoir that remains "frozen in
time", with no genetic evidence for new cycles
of virus replication.1

New evidence appears to confirm that effective HAART can
reduce viral replication to zero.
This finding was relevant in the context of
other discussions about drug toxicities and
management of patients with HAART at the
conference. Several speakers discussed the
concept of "substitution" - substituting triple
NRTI or NRTI + NNRTI regimens for the more
potent NRTI + PI regimen when patients
achieve non-detectable viral loads.2 This
observation leads to the next most obvious
study: what would be the impact of attacking
HIV with highly active drugs (three and four
drug regimens including PIs), reducing the
replication to zero, and then substituting a
new, more tolerable, regimen? This concept
was not addressed at the 8th CROI, but studies are sure to follow.

The New Guidelines: Use
Tools and Consult Experts

Updated US HHS guidelines3 were made
available on the web during the CROI conference; they are now available at:
http://www.hivatis.org. A yellow-shaded version of the guidelines is also available at this
site, highlighting changes from the last document. The most important change in the guideContinued on page 2
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Treatment Update...
(continued from page 1)

lines is to delay the initiation of HIV treatment until absolute CD4 T cell counts are
350 or lower and/or HIV RNA viral loads
are 55,000 or higher (Refer to HEPPigram
Table 2 page 8 ). Some experts disagreed
with this decision, which appears to deemphasize well-known data on the risk of
progression to AIDS at higher viral loads
(see Table 1). Treatment should be initiated by an HIV treatment expert who takes
into consideration the 'willingness' of the
individual to begin therapy, the degree of
existing immunodeficiency as determined
the CD4 T cell count, the risk of disease
progression as determined by the CD4 T
cell count and the plasma viral RNA, the
potential benefits and risks of therapy, and
the likelihood of adherence.
Clinical experts at the CROI meeting cautioned against oversimplification in the
rush to delay treatment. Three key components of the guidelines deserve emphasis here: (1) treatment should not be terminated in patients who have already
begun treatment based on guidelines distributed prior to this year; (2) careful monitoring of CD4 T cell count and viral load
are critical components of HIV treatment
and most experts would advise checking
these parameters at least every three
months because patients often experience sudden declines; (3) use of experts
to prescribe and adjust HIV treatment is
increasingly important.
CD4 T Cell Count and Viral Load: Tools
for HIV Management
The CD4 T cell count (CD4) and the viral
load (VL) are the two most important tools
in the HIV specialist's armamentarium.
RNA-PCR (Roche) is the only FDA
approved viral load monitoring tool. These
two lab tests provide information on the
HIV stage of disease and the likelihood of
progression. As can be seen from Table 1,
the chance of progressing to AIDS at a
CD4 of 350 and VL of 50,000 is 36.4%
after three years. Both the CD4 T cell
count and the VL should be measured (at
least twice, to establish a firm baseline)
prior to initiating therapy; the VL should be
repeated between two to eight weeks
after initiation of therapy so as to establish
the rate of decline in response to therapy.
There should be a one-log decrease in VL
at this point to indicate response to therapy (this emphasis is new). At eight weeks,
if the VL is detectable (defined using the
ultrasensitive assay as a VL less than 50
copies per ml), adherence should be
checked, and the need to intensify or
change therapy should be considered.
VL and CD4 are also used to monitor the
success of therapy; these tests should be
repeated every three to four months.
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Table 1. Risk of Progression to AIDS Defining Illness in Treatment Naïve Patients*
IN PATIENTS WITH CD4 201-350 AND
PLASMA VIRAL LOAD (copies/ml) OF:

% AIDS (AIDS-defining complication)

RT-PCR

3 Years

6 Years

1501-7000
7001-20,000
20,001-55,000
> 55,000

0
6.9
36.4
64.4

20
44.4
72.2
89.3

*Data from the Multi-Center AIDS Cohort Study (MACS), adapted from Mellors JW, Rinaldo CR,
Gupta P, et al. Prognosis in HIV-1 Infection predicted by the quantity of virus in plasma. Science.
1996; 272:1167-1170, for inclusion in US Dept of Health and Human Services. Guidelines for the
use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: US Dept of
Health and Human Services; February 2001. P37. Online at http://www.hivatis.org.

Table 2. Test Plasma HIV RNA When the Following Clinical Indications
are Present:
G
G
G
G
G
G
G

Syndrome consistent with acute HIV infection
Initial evaluation of newly diagnosed HIV infection
Every 3-4 months in patients not on therapy
2-8 weeks after initiation of antiretroviral therapy
3-4 months after start of therapy
Every 3-4 months in patients on therapy
Significant decline in CD4+ T cells

Successful therapy is indicated by VL less
than 50 (note the new emphasis on ultrasensitive viral load testing). A VL increase
of three-fold or one log and CD4 T cell
decline in absolute numbers more than
30% percent (or more than 3% change in
CD4 T cell percentage) should be confirmed, adherence ascertained, and a
change of therapy should be considered
(see HEPPigram page 7).
Drug-Resistant Viruses Fuel Need for
HIV Drug Sequencing
Viral resistance testing (either genotyping
or phenotyping) is a new recommendation
included the HHS guidelines this year
(see Table 2). Genotyping detects mutations in the virus that are linked to
changes in drug sensitivity. Genotyping is
more rapid than phenotyping, but phenotyping is more precise (some mutations
are more or less relevant in vivo). There
was no recommendation to use one over
the other. Furthermore, expert advice on
the interpretation of genotyping results,
and a careful history of prior ART exposure are both recommended. In view of
reports at the CROI that up to 26% of
patients who are recently diagnosed harbor resistant virus, genotyping prior to initiation of therapy may become commonplace, particularly in cases where the
patient may have been exposed to a
heavily pretreated patient. The value of
baseline genotyping in chronically infected treatment naïve patients is less clear,
as resistant strains tend to fall to undetectable levels in untreated patients.
Interested clinicians should read the HHS
guidelines carefully or review the HEPP
News on resistance testing (online at
http://www.hivcorrections.org/archives/
sept00). In short, resistance mutations

can be archived and the patient's history
of prior exposure to ART, their current ART
regimen, and cross-resistance within
classes may have an influence on the outcome and interpretation of resistance
tests.
Acute HIV Infection
Between 10 and 50% of patients with
acute HIV infection present to clinicians
with symptoms. Less than 20% of these
individuals are correctly identified as having acute HIV. Data presented by Bruce
Walker (see STI section, page 4) suggests that early treatment may lower the
"setpoint" of HIV infection, possibly prolonging life and potentially permitting the
patient to stop therapy. The duration of
therapy of acute HIV infection is completely unknown at this time. Expert consultation should be obtained.

New approaches and Reevaluations of existing
approaches

Results from 144 weeks of the DPC 006
and DMP 006 studies were presented,
showing that the mean time to failure on
dual NRTI and NNRTI regimens will be
about 6 years. These results supported
the inclusion of efavirenz (Sustiva) in the
list of "first line" treatments in the new
HHS guidelines. Results of studies using
Lopinavir/Ritonavir (Kaletra) as initial therapy were also presented at the CROI,
showing excellent responses. Ritonavirboosted PI treatments Lopinavir/Ritonavir
and Indinavir/Ritonavir were two new
additions to the "recommended therapy"
list this year (see HEPPigram Table 1,
page 7).
Continued on page 4
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Letter from the Editor

Dear Colleagues,

The 8th Conference on Retroviruses and Opportunistic Infections (8th CROI) had little to
say about our patients in the correctional system, but provided a startling picture of the
global HIV/AIDS epidemic, of which our patients are an integral part.
"Just saying no" to sex has the same impact on HIV transmission anywhere in the world, but
differences between the HIV prevalence rates distinguish the impact of "just saying yes" in
North Dakota and the Congo, according to Dr. Kevin DeCock of the Center for Disease
Control.1 In areas of the world where most individuals are unaware of their HIV status until
they are dying from AIDS, these individuals are highly likely to transmit the virus to their sexual partners, who then transmit to others, including their children. The impact of "just saying
yes" without knowledge of HIV infection on sub-Saharan Africa has been catastrophic: AIDS
is decimating the ranks of productive adult workers (including health care workers), impoverishing families and dramatically increasing the number of children orphaned by AIDS.
While DeCock decried international response to this human emergency of enormous scale,
he did not mention in his speech problems closer to home - such as the impact of HIV/AIDS
on selected sectors of US populations including African Americans, women, and incarcerated populations, even though there were many parallels.
This issue of HEPP News brings you commentary and news from the 8th CROI that is relevant to clinical practice in the correctional setting. After reviewing this issue, readers should
be able to describe the new changes in the HHS guidelines regarding HIV treatment and
resistance testing, how fusion inhibitors may become part of HIV antiretroviral therapy, and
explain why strategic treatment interruption is not recommended. Our next issue will cover
tuberculosis and HIV infection.
We apologize for the tardiness of this issue, but we have a good excuse! Our layout editor
delivered her first child, a baby boy, on Valentines Day. HEPP News welcomes the new
addition to the staff.
Thank you for your continued support and comments. Be sure to visit us online at
www.HIVcorrections.org!
Sincerely,
Anne S. De Groot, MD

Joseph

3

The editorial board and contributors to HEPP
News include national and regional correctional
professionals, selected on the basis of their
experience with HIV care in the correctional
setting and their familiarity with current HIV
treatment. We encourage submissions, feedback, and correspondence from our readership.

Bick, MD

1 DeCock K. Keynote Lecture - Heterogeneity and public health in the global HIV/AIDS epidemic. 8th CROI; February 4-8, 2001; Chicago, Illinois. Abstract L2.
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Treatment Update...
(continued from page 2)

Improved formulations of ART medications
are permitting researchers to address the
topic of once-daily therapy, an innovation in
treatment that may improve adherence in
correctional settings and methadone programs. Italian researchers and French
researchers showed outcomes from treatment with once-daily didanosine (Videx,
300 mg), lamivudine (3TC, Epivir, 300 mg),
and efavirenz (Sustiva, 600 mg) in 75
patients naive to antiretroviral therapy.4
There is a growing list of ART drugs that
can be considered for once-daily therapy,
including DDI, 3TC (and newer derivatives),
efavirenz, nevirapine (Viramune), abacavir
(Ziagen) and amprenavir/ritonavir. This
writer believes that these newer, more tolerable regimens will result in yet another
revision of the guidelines next year.
New "entry blocking" Treatments
Viral entry into the host cell is a new target
for HIV drugs. However, compounds that
are developed to block entry of virus will be
ineffective against virus that spreads by
syncitia formation (cell-to-cell) and will not
have any effect on non-replicating virus. It is
likely that entry blockers will be used in
combination with existing antiretroviral
agents. Two classes of entry inhibitor are in
development - fusion inhibitors and
chemokine receptor blockers. These drugs
are probably most effective when used in
combination.
Fusion Inhibitors
T-20 (made by Trimeris) is the first member
of the fusion inhibitor class. T-20 is a very
short (39 amino acid) peptide that binds to
one of the two helical domains of gp41.
Gp41 is a spring-loaded HIV-1 protein that
is activated when CD4 binds to HIV gp-120.
The fusion action of gp41 is inhibited if its
two helical domains cannot fold together.
T20 binds to gp41, effectively keeping the
protein from functioning. Unfortunately, this
drug is a peptide, so it cannot be given orally. It is given as an injection, and more than
10% of patients develop reactions at the

visit HEPP News online at www.hivcorrections.org
injection site. Previous studies of T20 without HAART showed that resistance is rapid
to develop. However, when used in combination with other ART, the drug appears to
be effective. In a "late breaker report",
Lalezari reported on a Phase I (dose finding) study of 71 patients receiving combination HAART and T20. By week 16, patients

STI are viewed by patients as
a welcome respite to therapy this is probably one of
the main motivators for
research in this area.
participating in the T-20 arms of the study
had 0.5 log lower HIV RNA levels than
patients in the non T-20 arms.5 In the future,
due to the need for injections, T20 will probably be used only in the setting of extensive
resistance. Trimeris is also developing variant of this drug, called T-1249.
CCR5 Blockers
Another key protein involved in HIV entry is
CCR5 (chemokine receptor 5). This protein
is ubiquitous on immune cell membranes.
Blocking this receptor is believed to be
safe, and important, since individuals who
have homozygous deletion of this gene
appear not to have any increased susceptibility to infections and are almost completely resistant to HIV infection. The CCR5
blocking-compound furthest along in development is a Shering Plough drug, SCH-C.6
Un-Successful and Un-Structured
Treatment Interruptions (STI)
Structured treatment interruptions (STI)
were addressed by a number of the speakers at the 8th CROI. The rationale for STI is
that CD4 T cell replication is achieved in
effective HAART, so providers were interested in whether patients could contain
virus (they cannot) and whether "autovaccination" might improve immune responses
to the virus (they do not). Furthermore,
there is a hope that virus will revert to wild
type (it does not, as resistance mutation are
archived in latently infected T cells). Finally,
STI are viewed by patients as a welcome
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respite to therapy - this is probably one of
the main motivators for research in this
area.
STI may have a role in EARLY (before seroconversion) treatment of HIV, as reported
by Bruce Walker.7 However, based on the
results reported at the 8th CROI, it is too
early to know whether STI is viable options,
and treatment of acute HIV infection should
be supervised by an HIV specialist. At present, no guidelines exist as to whether
treatment may be stopped after initial therapy or whether it should be continued indefinitely (which would run counter to the HHS
guidelines stating treatment should be
delayed until later in the course of disease).
Therapy-Related Adverse Events
Adverse events were one of the major reasons for changes in the HHS guidelines.
Details on mitochondrial toxicity and hepatic steatosis, fat maldistribution, rash, and
diabetes/pancreatitis are given in the new
guidelines. These topic and neuropathy
were also covered at the 8th CROI. In short,
concern about side effects resulted in
changes in the guidelines for the use of
antiretroviral therapy this year (see
HEPPigram Table 1, page 7 and the
upcoming HEPP News issue in April on
neuropathy).

There's Always More

A special feature for this month, the Rapid
Report on page 6 has further news from the
conference. In the upcoming issues we will
cover more topics from the 8th CROI such
as neuropathy and the CDC's new program
on National HIV Prevention. In the meantime, visit the conference website
http://www.retroconference.org/2001 or
Medscape at http://www.medscape.com.
Funding for this conference coverage
was provided by educational grants
from Agouron Pharmaceuticals, DuPont
Pharmaceuticals Company, Hoffman La
Roche, and Boehringer-Ingelheim/Roxane
Laboratories.

* Consultant & Speakers Bureau: Agouron Pharmaceuticals, Dupont, Merck, Roche, Boehringer-Ingelheim/Roxane Laboratories

REFERENCES:

1. Robert Siliciano Viral Reservoirs and Ongoing Virus Replication in Patients on HAART: Implications for Clinical Management. 8th CROI. Abstract L5
2. Becker S, Rachlis A, Gill J, et al. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads -- a
prospective, randomized, multicenter, open-label study (DMP-049). 8th CROI. Abstract 20.
3. US Dept of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: US
Dept of Health and Human Services; February 2001. Published online at: http://hivatis.org/trtgdlns.html.
4. Maggiolo F, Migliorino M, Maserati R, et al. Once-a-day treatment for HIV infection: final 48-week results. 8th CRO. Abstract 320.
5. J. Lalezari, J. Drucker, R. Demasi, S. Hopkins, and M. SalgoA Controlled Phase II Trial Assessing Three Doses of T-20 in Combination with Abacavir,
Amprenavir, Low Dose Ritonavir and Efavirenz in Non-Nucleoside Naïve Protease Inhibitor Experienced HIV-1 Infected Adults . 8th CROI. Abstract LB5
6. Reyes G. Development of CCR5 Antagonists as a New Class of Anti-HIV Therapeutic. 8th CROI. Abstract L11.
7. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000; 407:523-526. 407:523-526.,
reported by Bruce Walker in his talk: Structured treatment interruption: novel strategy or oxymoron? State-of-the-art lecture and summary. 8th CROI.
Abstract 266.

February 2001

Volume 4, Issue 2

Spotlight:

visit HEPP News online at www.hivcorrections.org

5

Directly Observed Therapy for HIV Therapy in Corrections: Ready or Not?

A point and counterpoint discussion of the use of Directly Observed Therapy for HIV treatment in the correctional setting.
Dr. Margaret Fischl, director of the Miami AIDS Clinical Research Unit, presented at the CROI (Feb. 7, 2001) her comparison of the outcomes of treatment naïve ACTG subjects enrolled in antiretroviral treatment trials conducted both at the Miami AIDS Clinical Research
Unit and the Florida state prison (CROI Abstract 528). Within the prison system, inmate-patients are administered antiretrovirals under
direct observation (DOT). Fischl examined the viral load responses to study regimens among 50 prisoners receiving their study medications via DOT and 50 AIDS Clinical Research Unit outpatients receiving study medication in the conventional, unobserved way. The
two groups were different demographically, with more of the incarcerated patients likely to be African American, Latino, male and to have
a history of injection drug use. Further, the patients in prison had lower CD4 cell counts and higher viral loads. After 24 weeks, 90% of
the prisoners had viral loads that were below 50 copies/mL while 77% of the free subjects achieved this goal at this time point. These
differences in response rates remained out to 90 weeks of follow-up and were highly statistically significant. In general, simpler regimens of three drugs had better response rates than more complex four-agent combinations.

POINT

By David A. Wohl, M.D.*, Director, Central Prison Infectious
Disease Service, UNC Central Prison Hospital, North Carolina
Department of Corrections
Reprinted with permission from the National AIDS Treatment
Advocacy Project.
While on the face of it, these results seem to be a resounding
endorsement for DOT, several questions lurk. Although all the
incarcerated subjects received DOT, it is not clear this was
responsible for their excellent responses (above the enviable
rates seen among the free patients). There are many confounding factors that could have contributed to the inmates' success including the regimented structure of prison life, the influence of correctional medical staff or just simply having 'three
hots and a cot' and (relatively) limited access to crack cocaine.
The differences between the two groups of patients extend
beyond the presence or absence of DOT and, therefore, DOT
alone cannot be regarded as the crucial determinant of the
observed results. In the North Carolina Department of
Corrections, we have found DOT adds nothing to self-administration of antiretrovirals (Wohl DA, Stephenson B, et al.
Adherence to Directly Observed Therapy (DOT) of
Antiretrovirals in a State Prison System [357]. Infectious
Disease Society of America, New Orleans, 2000).
In fact,
many inmates complain that DOT renders them conspicuous as
being HIV-infected as they stand in line for medication and
therefore, opt not to present for DOT. Under such conditions,
DOT may present an obstacle rather than a path to adherence.
Before DOT is used as an intervention to enhance adherence,
some prospective investigation on both sides of the barbed wire
is warranted beyond this interesting first step.

COUNTERPOINT

By David Thomas, M.D.**, Director of Health Services, Florida
Department of Corrections
As a co-author of this presentation and the person responsible
for all of the Health Services in the Florida Department of
Corrections, let me respond to Dr. Wohl's concerns. We strongly agree that medical therapy in isolation (e.g. DOT) may be
only one of the contributing factors, and may have reduced
opportunities for better diets and illicit drug use. The authors
strongly feel that the adherence to medical pharmacotherapeutic regimen is the key reason for improvement. To test this
hypothesis, another study is planned of two groups, both of
which are incarcerated. In systems that do not use DOT, but
have the other realities of prison life, rates of viral load improvement match the community setting. Clearly, there are some situations and conditions where DOT can lead to aversive elements, so the initiation must be done with care and sensitivity.
In Florida, we have been using DOT for a long time, and our
staff and inmates report they are comfortable with it. Of the
2,700 inmates with HIV, the vast majority are on treatment
(2,250). Of the remainder, the overwhelming majority are not
captured by the guidelines (and we still use the more aggressive 5-10,000 viral load cut-off for treatment). It is only a small
minority who refuse because of direct observed therapy. Most
cite other reasons.
HEPP Editor's Note: Clearly, there is a use for DOT in some
settings, but its success will vary between facilities. There is an
acute need for further study.

*Speakers Bureau: Abbott Laboratories, GlaxoSmithKline and Merck & Co.
**Consultant & Speakers Bureau: Agouron Pharmaceuticals, Bristol- Myers Squibb , GlaxoSmithKline, Boehringer-Ingelheim/Roxane
Laboratories, Roche Pharmaceuticals, Merck & Co.

CME is Now Available Online at www.hivcorrections.org:

HEPP readers are now able to take HEPP News' continuing medical education (CME) tests online at
http://www.HIVcorrections.org. Any internet browser will enable you to take the HEPP News CME tests every month.
Your test results will be registered with the Brown Medical School Office for Continuing Medical Education. When you
pass the test, you can either download your CME certificate from the website or request Brown to send the certificate in
the mail. Try it out this week!
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The Latest News From the 8th Conference on Retroviruses
and Opportunistic Infections

By Joseph Bick, M.D.*, Director, HIV Treatment Services, California Medical Facility -Vacaville, California Department of Corrections
ANTIRETROVIRAL CHEMOTHERAPY
Although promising data was presented on new NNRTIs and PIs
that are more potent and demonstrate improved resistance profiles, none of them are likely to be available for widespread use
within the coming year. Likewise, fusion inhibitors and IL-2 require
further study before entering clinical practice. What follows are
comments on a few abstracts that deal with simplified preparations
or pharmacokinetic (PK) enhancement of existing agents, which
are more immediately applicable to clinical care. Full texts of all
conference abstracts are available at http://www.retroconference.org/2001.
Abstracts 315 and 316 demonstrated Trizivir's equivalent activity to
its components, AZT, 3TC, and abacavir. For selected patients, this
offers the simplicity of one pill twice daily .
Abstracts 318 and 319 supported the efficacy of the new extended
release formulation of ddI EC as compared to either standard ddI
or to other HAART regimens. Enteric-coated Didanosine is easier
to take and leads to less drug-drug interactions than standard ddI
tablets.
Abstracts 332, 405, and 739 evaluated various dosing regimens
for the ritonavir (RTV) enhancement of amprenavir (AMP).
Combining data from these studies, the following regimens all
appear to have similar efficacy to the standard dosing of AMP
1200 mg bid: AMP 600/RTV 100 bid, AMP 450/RTV 200 bid, and
AMP 1200/RTV 200 or 400 qd. All of the alternative regimens
decrease pill burden, increase C min (less opportunity for resistance), decrease C max (less toxicity) and lead to similar AUC.
The 450/200 option appears to have the best overall PK parameters, and also obviates the need for dose modification when used
with NNRTIs.
Abstracts 334, 335, and 336 studied the PKs of ritonavir enhancement of indinavir (IDV). Pooling data from these three studies, the
standard dosing of IDV 800 mg tid had similar PK to IDV 800/RTV
100 bid, IDV 400/RTV 400 bid, and IDV 1200/RTV 200 qd. The bid
and qd regimens provided less frequent dosing and eliminated the
necessity for dosing on an empty stomach. Overall, the 400/400
option appeared to have the best PK parameters with the least
side effects.
Abstracts 18 and 321 provided additional data on the once daily
use of emtricitibine (FTC), a NRTI with greater potency and prolonged half-life as compared to 3TC.
In conclusion, virtually every HAART regimen can now be delivered in two daily doses, and there are an increasing number of
options for once daily therapies. In the correctional setting, this will
increase adherence and simplify directly observed therapy for
those systems that chose to use it.
EPIDEMIOLOGY
The following four abstracts demonstrate the overwhelming ongoing need for inmate peer education for all prisoners- whether
known to be infected or not.
G Abstracts 211 (NYC) and 212 (6 U.S. cities) both studied young
men who have sex with men (MSM) and found an alarming rate of
*No affiliations to disclose.

unprotected anal sex within the past six months (~50% of those
interviewed). Both studies also found rates of HIV seropositivity
among African American men of approximately 30%--over twice as
high as those from all other racial/ethnic backgrounds.
G Abstract 213 from Los Angeles found that those MSM who had
confidence that HAART decreases the risk of HIV transmission
were more likely to have had recent unprotected anal sex.
G Abstract 261 from Amsterdam found a marked increased rate
of syphilis and gonorrhea (GC) among MSM. Among HIV seropositive MSM, those who experienced a HAART induced rise in CD-4
and drop in viral load were found to then increase their rate of
unprotected sex with casual partners.
TRANSMISSION
A number of studies have shown that HAART induced drops in HIV
viral load decrease the rate of transmission to seronegative partners. Abstract 221 from Thailand corroborated such prior studies
by finding no cases of transmission when the HIV viral load was
<1094.
Prior studies have shown that the presence of ulcerative genital
disease increases the transmission rate of HIV. Abstract 222
demonstrated that the presence of GC urethritis also markedly
increases HIV transmission, reminding us of the unique opportunity that we have in correctional medicine to impact the spread of
disease by diagnosing and treating STDs.
Lastly, an important study from the Kaiser HMO system in
California (219) evaluated 416 individuals recently diagnosed with
HIV. At the time of diagnosis, 44% already had CD-4 <200, with
19% <50. Since HAART is most effective when instituted earlier in
the course of the disease (see abstracts 341 and 342), many
patients are being diagnosed too late for optimal benefit.
Furthermore, 40% of these newly diagnosed individuals had presented with known HIV risk factors at least 12 months before they
were eventually tested- reflecting missed opportunities for earlier
diagnosis and treatment. Risk factors included oral infection,
pneumonia, unexplained fever >100, herpes zoster, seborrheic
dermatitis, night sweats, and unexplained weight loss.
Undiagnosed persons not only go untreated, but they also
unknowingly pass the virus to others. How often in our own correctional practices have we missed opportunities for earlier diagnosis?
HCV ACCELERATES HIV AND VICE VERSA
The impact of HIV on HCV and vice versa has been the subject of
much debate. CROI reports contributed to the confusion. In a population of hemophiliacs, Dr Eric Daar found a close linear relationship between HCV RNA level and abnormal liver function tests
(SGOT or ALT). The HCV viral load level (by branched-chain DNA)
appeared to independently predict an increased risk of HIV clinical
progression (abstract 35). This observation was confirmed in a
Swiss cohort, described in the Lancet (Greub G, et al. Lancet,
2000;356:1800-1805. However, a report by Sulkowski at CROI
contraindicated these findings, suggesting that risk of progression
was more linked to lack of access to medical care (for HIV) in his
cohort of African American patients who had HIV and HCV coinfection (abstract 34).
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Treatment for HIV Infection

Table 1. Initial Treatment for Established HIV Infection

This table provides a guide to the use of available treatment regimens for patients with limited or no prior experience on HIV therapy.
In accordance with the established goals of HIV therapy, priority is given to regimens for which clinical trials data suggest the following: sustained suppression of HIV plasma RNA (particularly in patients with high baseline viral load) and sustained increase in CD4+ T
cell count (in most cases over 48 weeks), and favorable clinical outcome (i.e. delayed progression to AIDS and death). Particular
emphasis is given to regimens that have been compared directly with other regimens that perform sufficiently well with regard to these
parameters to be included in the "Strongly Recommended" category. Additional consideration is given to the regimen's pill burden,
dosing frequency, food requirements, convenience, toxicity, and drug interaction profile compared with other regimens.
It is important to note that all antiretroviral agents, including those in the "Strongly Recommended" category, have potentially serious
toxic and adverse events associated with their use. The reader is strongly encouraged to consult the HHS HIV Treatment Guidelines
(available at www.hivatis.org) while formulating an antiretroviral regimen.
Antiretroviral drug regiments are comprised of one choice each from columns A and B. Drugs are listed in alphabetical, not priority,
order.

Strongly Recommended

Column A
Efavirenz (Sustiva, EFV)
Indinavir (Crixivan, IDV)
Nelfinavir (Viracept, NFV)
**Ritonavir (Norvir, RTV)+ Indinavirab
**Ritonavir/Lopinavir (Kaletra)a
Ritonavir + Saquinavira (SGCc or HGC)

Column B
Stavudine (Zerit, d4T)+ Didanosine (Videx, ddI,
ddi EC)d
Stavudine + Lamivudine (Epivir, 3TC)
Zidovudine (Retrovir, ZDV) + Didanosine
Zidovudine + Lamivudine (Combivir)

Recommended as
Alternatives

Column A
Abacavir (Ziagen, ABC)
Amprenavir (Agenerase, AMP)
Delavirdine (Rescriptor, DLV)
Nelfinavir + Saquinavir
Nevirapine (Viramune, NVP)
Ritonavir
Saquinavir-SGC
Trizivir (Abacavir, Lamivudine, Zidovudine)

Column B
Didanosine + Lamivudine
Zidovudine + Zalcitabine (Hivid, ddC)

No Recommendation:
Insufficient Datae

Hydroxyurea in combination with
antiretroviral drugs
**Ritonavir + Amprenavira
Ritonavir + Nelfinavira

Not Recommended:
Should Not Be Offered

All monotherapies, whether from
Column A or Bf
Column A
Saquinavir-HGCg

Column B
Stavudine + Zidovudine
Zalcitabine + Didanosine
Zalcitabine + Lamivudine
Zalcitabine + Stavudine

a See Guidelines page 16 for more information on optimizing protease inhibitor exposure with ritonavir.**
b Based on expert Opinion**
c Saquinavir-SGC, soft-gel capsule (Fortovase); Saquinavir-HGC. Hard-gel capsule (Invirase).**
d Pregnant women may be at increased risk for lactic acidosis and liver damage when treated with the combination of stavudine and

didanosine. This combination should be used in pregnant women only when the potential benefit clearly outweighs the potential risk.
e This category includes drugs or combinations for which information is too limed to allow a recommendation for or against use.**
f Zidovudine monotherapy may be considered for prophylactic use in pregnant women with low viral load and high CD4+ T cell counts
to prevent perinatal transmission, as discussed under Considerations in the Pregnant Woman" in the Guidelines.
g Use of Saquinavir-HGC (Invirase) is not recommended, except in combination with ritonavir.
**Changes from last year's guidelines are starred.

( HEPPigram continued on page 8 )
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Save the
Dates
American Correctional Health
Services Multidisciplinary
Training Conference
March 15-18, 2001
Atlanta, Georgia
Call: 877.918.1842
Visit: www.corrections.com/
achsa/conferences.html
Implementing HIV Treatment
Guidelines in Corrections
Panel organized by HEPP at the
National AIDS Update Conference
(March 20-23)
March 21, 2001
11:00am-12:30pm
San Francisco, California
Conference sponsored by amfAR
For information on the panel,
Call: 401.863.2180
Email: bstubb@Brown.edu
For information on the conference,
Call: 514.874.1998
Visit: http://www.nauc.org
United States Conference
on AIDS (USCA)
September 13-16, 2001
Fort Lauderdale, Florida
Abstract Deadline: April 2, 2001
Call: 202.483.6622
Email: info@nmac.org
Visit: www.usca.org
Clinical Updates in Correctional
Health Care: 6th Semi-Annual
Spring Educational Conference
May 5-8, 2001
Las Vegas, Nevada
Sponsored by: NCCHC and ACHP
Call: 773/880.1460
Fax: 773/880.2424
Visit: http://www.ncchc.org/
conference/clinical.html
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Table 2. Indications for the Initiation of Antiretroviral Therapy in the
Chronically HIV-1 Infected Patient
Clinical Category CD4+ T Cell Count Plasma HIV RNA

Recommendation

Symptomatic

Any value

Any value

Treat

Asymptomatic,
AIDS

<200/mm3

Any value

Treat

Asymptomatic

>200/mm3 but
<350/mm3

Any value

Treatment should generally
be offered, though controversy exists.*

Asymptomatic

>350/mm3

Some experts would rec>30,000 (bDNA)
or >55,000 (RT-PCR) ommend initiating therapy,
recognizing that the 3-year
risk of developing AIDS in
untreated patients is >30%.
In the absence of very high
levels of plasma HIV RNA,
some would defer therapy
and monitor the CD4+ T
cell count and level of plasma HIV RNA more frequently. Clinical outcomes
data after initiating therapy
are lacking.

Asymptomatic

>350/mm3

Many experts would defer
<30,000 (bDNA)
or <55,000 (RT-PCR) therapy and observe, recognizing that the 3-year risk
of developing AIDS in
untreated patients is <15%.

*Clinical benefit has been demonstrated in controlled trials only for patients with CD4+ T cells
<200/ mm3. However, most experts would offer therapy at a CD4+ T cell threshold <350/mm3. All decisions to initiate therapy should be based on prognosis for disease-free survival in the absence of treatment, as determined by the CD4+ T cell count and level of plasma HIV RNA shown in Table 5, the
potential benefits and risks of therapy shown in Table 4, and the willingness of the patient to accept therapy. For further information, see "Considerations for Initiating Therapy in the Patient with Asymptomatic
HIV Infection," page 6 of the HHS Guidelines.
These tables were taken from US Dept of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: US Dept of Health and Human
Services; February 2001. P44 and 38. Online at http://www.hivatis.org.

Resources
Websites:

Other News . . .

We have a new sign-up
number, so tell your
colleagues to sign up for
HEPP News by calling
1.800.748.4336.
(You can also sign up on
the website at
www. hivcorrections.org or
by faxing 1.617.770.3339
or emailing
hepp@corrections.net.)
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*Updated DHHS HIV/AIDS Treatment
Guidelines
http://www.hivatis.org
8th Conference on Retroviruses and
Opportunistic Infections
http://www.retroconference.org/2001
Medscape Coverage of the 8th CROI
http://www.medscape.com/conferences/Retro
virus2001
Medscape HIV/AIDS Online
http://www.medscape.com/Home/Topics/
AIDS/AIDS.html

HIV Treatment Websites:
HIV/AIDS Treatment Information Service
http://www.hivatis.org
HIV Insite
http://hivinsite.ucsf.edu/
AEGiS: the largest HIV/AIDS resource on
the internet
http://www.aegis.com
The Body: An AIDS and HIV information
Resource
http://www.thebody.com
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. A
minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through
Feb. 28, 2002. The estimated time for completion of this activity is one hour and there is no fee for participation.

CME is now available ONLINE at www.hivcorrections.org
1. Which of the following statements is false?
a) T memory cells act as a long-lived reservoir for HIV
infection.
b) HAART can dramatically interrupt the replication of HIV in
activated T cells
c) Patients who have been started on ART should stop
treatment if their CD4 T cell count is above 350.
d) Adherence to HAART can "freeze" HIV in time, preventing
the evolution of new resistance mutations.
e) The decision to modify HIV treatment guidelines was based
on evidence of long-term drug toxicity
2. When should plasma RNA be measured?
a) Patient presents with syndrome consistent with acute HIV
infection.
b) As part of initial evaluation of newly diagnosed HIV
infection.
c) 2-8 weeks after initiation of antiretroviral therapy.
d) 3-4 months after initiation of antiretroviral therapy.
e) Patient presents with clinical evidence or significant decline
in CD4+ T cell count.
f) All of the above
g) None of the above
3. The new guidelines indicate that physicians should delay the
initiation of HIV treatment until absolute CD4 T cell counts are
_____ and/or HIV RNA viral loads are ______.
a) CD4 T cell count <500 and/or HIV RNA viral load >5000.
b) CD4 T cell count <450 and/or HIV RNA viral load >30,000.
c) CD4 T cell counts <350 and/or HIV RNA viral load >55,000.
d) CD4 T cell count >350 and/or HIV RNA viral load >55,000.
4. Which of the following are true?
a) Response to therapy should be indicated by a one-log
reduction in viral load.
b) Viral resistance testing should be included in HIV treatment
management.
c) Ultrasensitive viral load testing should be included in HIV
treatment management.
d) All of the above.
e) None of the above.

5. When presented with an asymptomatic patient with AIDS,
CD4+ T cell <200/mm3 and plasma RNA of 50,000, you should:
a) Treat.
b) Consult an expert and consider treatment.
c) Obtain a genotype.
d) Defer treatment.
6. CD4+ T cell count and viral load should be monitored every
___ months because patients often experience sudden declines.
a) 2
b) 3
c) 6
d) 12

HEPP News Evaluation
5 Excellent

4 Very Good

3 Fair

2 Poor

1 Very Poor

1. Please evaluate the following sections with respect to:
educational value
clarity
Main Article
5 4 3 2 1
5 4 3 2 1
Spotlight
5 4 3 2 1
5 4 3 2 1
HEPPigram
5 4 3 2 1
5 4 3 2 1
Save the
Dates
5 4 3 2 1
5 4 3 2 1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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